Tislelizumab
Extragonadal Yolk Sac Tumors
BeOne Medicinesmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Extragonadal Yolk Sac Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
Sc-Car.Gpc3Xil15.21 Car T Cells Seattle Children's Hospital | Phase 1 | CC |
Care T Cells Baylor College of Medicine | Phase 1 | CC |
Catch T Cells Baylor College of Medicine | Phase 1 | CC |
21.15.gpc3-car t cells Baylor College of Medicine | Phase 1 | CC |
Bgb-B2033 BeOne Medicines | Phase 1 | CC |
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →